Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/13/2005WO2005095604A1 Rf rp transgenic animal
10/13/2005WO2005095600A1 Heparin-binding protein having heparan sulfate sugar chain attached thereto, process for producing the same and medicinal composition containing the same
10/13/2005WO2005095598A1 Cancer antigen peptide originating in wt1
10/13/2005WO2005095594A1 Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
10/13/2005WO2005095593A1 Method for modification of nmda receptors through inhibition of src
10/13/2005WO2005095592A2 Subtilase variants having altered immunogenicity
10/13/2005WO2005095452A1 Calcium ion leakage inhibitors
10/13/2005WO2005095450A2 Therapeutic use of a growth factor, nsg33
10/13/2005WO2005095445A1 Novel basic antibacterial peptide and utilization thereof
10/13/2005WO2005095444A2 Synthetic peptides containing the motif ‘ywwlxp’ as anthrax toxin antidotes
10/13/2005WO2005095443A1 Drug delivery system using peptide modification
10/13/2005WO2005095442A1 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
10/13/2005WO2005095441A1 Epithelial cell growth promoter
10/13/2005WO2005095412A1 Antiallergic agent
10/13/2005WO2005095331A1 Agent for binding sugar chain to peptide
10/13/2005WO2005094912A1 Transplantation graft with enhanced angiogenic effect
10/13/2005WO2005094890A1 Composition for increasing body height
10/13/2005WO2005094889A1 Remedy or preventive for arthritis
10/13/2005WO2005094888A1 Damaged tissue therapeutic agent and therapeutic method
10/13/2005WO2005094887A1 sFRP EXPRESSION POTENTIATING AGENT
10/13/2005WO2005094878A1 Composition having antitumor effect
10/13/2005WO2005094876A1 Diagnostics and therapeutics for diseases associated with p21 (cdkn1a)-activated kinase 2 (pak2)
10/13/2005WO2005094875A1 Use of epi-hne 1-4
10/13/2005WO2005094874A1 Medical use of alpha-mannosidase
10/13/2005WO2005094873A1 Factor ixa for the treatment of bleeding disorders
10/13/2005WO2005094872A1 Polypeptide inducing the secretion of angiopoietin
10/13/2005WO2005094871A2 Bmp-3 propeptides and related methods
10/13/2005WO2005094870A2 Use of osteopontin fragment svvglr-derived peptides for the treatment of ischemic diseases
10/13/2005WO2005094869A1 Compositions and methods for improved mucus function
10/13/2005WO2005094868A1 Use of repeat sequence protein polymers in personal care compositions
10/13/2005WO2005094867A1 Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
10/13/2005WO2005094866A1 Adiponectin expression inducer and utilization of the same
10/13/2005WO2005094865A1 Compound having angiogenic effect
10/13/2005WO2005094863A1 Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors
10/13/2005WO2005094862A1 Compositions and method for alleviating inflammation and oxidative stress in a mammal
10/13/2005WO2005094854A1 Modified nutraceutical composition
10/13/2005WO2005094818A1 Azabicyclo-octane inhibitors of iap
10/13/2005WO2005094579A1 Synergistic antimicrobial compositions and methods for reducing biofilm formation
10/13/2005WO2005094533A2 Trail-r as a negative regulator of innate immune cell responses
10/13/2005WO2005094453A2 Cospeptin, cosmedin and their uses
10/13/2005WO2005094423A2 Selective inhibition of proteasomes of tuberculosis and other bacteria
10/13/2005WO2005094420A2 Materials and methods for treatment of inflammatory and cell proliferation disorders
10/13/2005WO2005094278A2 N-acylated chitinous polymers and methods of use thereof
10/13/2005WO2005094265A2 Self assembling activation agents targeted using active drug release
10/13/2005WO2005082415A3 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
10/13/2005WO2005081613A3 Pharmaceutical compositions of peptides secreted by the venom glands of snakes
10/13/2005WO2005079766A3 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
10/13/2005WO2005070450A8 Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds
10/13/2005WO2005063290A3 Use of il-18 binding protein in inflammations
10/13/2005WO2005056581A3 Peptide able to specifically bind a chemokine receptor and use thereof
10/13/2005WO2005056577A3 Peptide inhibitors of hiv
10/13/2005WO2005051291A3 B-cell-targeted toxin for immuno response reduction
10/13/2005WO2005049105A8 Medical implants and anti-scarring agents
10/13/2005WO2005026741B1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
10/13/2005WO2005025595A3 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
10/13/2005WO2005025552A3 Protein binding compounds
10/13/2005WO2005019474A3 Human autism susceptibility gene and uses thereof
10/13/2005WO2005010205A3 Biomarkers fo aggrecanase activity
10/13/2005WO2004104176A3 Method for the identification of inhibitors of ornithine carbamoyltransferase, ketol-acid reductoisomerase, and fungal pathogenicity-conferring gene as antibiotics
10/13/2005WO2004096118A3 Composition for improving cognition and memory
10/13/2005WO2004087065A8 Compositions for induction of a therapeutic response
10/13/2005WO2004064717A3 Cop 1 for treatment of inflammatory bowel diseases
10/13/2005WO2004062578A3 Methods for reducing mortality associated with acute myocardial infarction
10/13/2005WO2003031643A3 Methods for regulating co-stimulatory molecule expression with reactive oxygen
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050228171 Purification method
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228013 e.g. 4-[3-(Furo[3,2-c]pyridin-2-yl-carbonyl)-thioureido]-benzoic acid butyl ester; viricide; hepatitis C (HCV) infections, cirrhosis, end-stage liver disease, and liver cancer; side effects reducer
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050227951 Verification of translation
10/13/2005US20050227941 Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
10/13/2005US20050227938 Antisense modulation of TFAP2C expression
10/13/2005US20050227937 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
10/13/2005US20050227929 parecoxib sodium and antineoplastic agent chosen from list of 150 compounds, vaccines, and biodrugs such as polyglutamic acid-paclitaxel
10/13/2005US20050227926 E.g., 2S [[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; in particular as inhibitors of HIV protease
10/13/2005US20050227925 Compositions capable of reducing elevated blood urea concentration
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227923 Stimulation of bone growth with thrombin peptide derivatives
10/13/2005US20050227922 Peptides/polypeptides prevent age-related neurodegeneration
10/13/2005US20050227921 Inhibition of FGF signaling
10/13/2005US20050227920 Methods for production of recombinant vascular endothelial cell growth inhibitor
10/13/2005US20050227919 DNA damage repair inhibitors for the treatment of cancer
10/13/2005US20050227918 Method for assaying susceptibility to cancer therapy in a subject by assaying for tumors of P53
10/13/2005US20050227917 Gene products differentially expressed in cancerous cells and their methods of use II
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227915 Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
10/13/2005US20050227913 Reducing the immunogenicity of a therapeutic peptide, polypeptide or protein (Factor VIII) by complexing it with a serine compound, phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid ore a phospholipid containing them; may be used to treat Hemophilia
10/13/2005US20050227912 Hemoglobin composed 2 polypeptides, each having a normal human hemoglobin alpha chain amino acid sequence, and 2 polypeptides, each having a normal normal bovine hemoglobin beta chain amino acid sequence; at least one polypeptide has a mutation that introduces a polymerization site; nucleic acid
10/13/2005US20050227911 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050227329 Recombinant fibroblast growth factor analogs
10/13/2005US20050227328 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/13/2005US20050227323 polynucleotide having nucleic acid sequences, encoding and expressing calcium-independent phospholipase A2 epsilon (iPLA2 epsilon ); for catalysis and hydrolysis of lipids in living cell biosystem; iPLA2 epsilon as a pharmacological target in drug screening anti-obesity drugs
10/13/2005US20050227320 For cleaving and sequencing polysaccharides such as glycosaminoglycans, removing polysaccharides from solution, inhibiting anticoagulant activity, inhibiting angiogenesis, treating cancer, inhibiting maternal malarial infection
10/13/2005US20050227302 Induction of apoptosis via ARTS-IAP complexes
10/13/2005US20050227295 Constitutively activated human G protein coupled receptors
10/13/2005US20050227287 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPSc
10/13/2005US20050227282 Human extracellular matrix-1
10/13/2005US20050227280 Proteases
10/13/2005US20050227279 Methods of using torsin proteins, to prevent protein misfolding and treat protein aggregation-associated disorders
1 ... 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 ... 3163